Your browser doesn't support javascript.
loading
Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer.
Gudenkauf, Lisa M; Chavez, Melody N; Maconi, Melinda Leigh; Geiss, Carley; Seyedroudbari, Ameen; Thin, Pan; Hoogland, Aasha I; Nguyen, Kathleen; Murthy, Vishnu; Armstrong, Wesley R; Komrokji, Khaled; Oswald, Laura B; Jim, Heather S L; El-Haddad, Ghassan; Fendler, Wolfgang P; Herrmann, Ken; Cella, David; Czernin, Johannes; Hofman, Michael S; Dicker, Adam P; Calais, Jeremie; Tagawa, Scott T; Gonzalez, Brian D.
Afiliación
  • Gudenkauf LM; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida; lisa.gudenkauf@moffitt.org.
  • Chavez MN; Participant Research, Interventions, and Measurements Core, Moffitt Cancer Center, Tampa, Florida.
  • Maconi ML; Participant Research, Interventions, and Measurements Core, Moffitt Cancer Center, Tampa, Florida.
  • Geiss C; Participant Research, Interventions, and Measurements Core, Moffitt Cancer Center, Tampa, Florida.
  • Seyedroudbari A; Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
  • Thin P; Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
  • Hoogland AI; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida.
  • Nguyen K; Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
  • Murthy V; Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
  • Armstrong WR; Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
  • Komrokji K; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida.
  • Oswald LB; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida.
  • Jim HSL; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida.
  • El-Haddad G; Department of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, Florida.
  • Fendler WP; Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium-University Hospital Essen, Essen, Germany.
  • Herrmann K; Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium-University Hospital Essen, Essen, Germany.
  • Cella D; Departments of Medical Social Sciences and Psychiatry and Behavioral Sciences, and Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Czernin J; Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
  • Hofman MS; Prostate Cancer Theranostics and Imaging Centre of Excellence, Cancer Imaging, Peter MacCallum Centre, Melbourne, Victoria, Australia, and MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
  • Dicker AP; Department of Pharmacology and Experimental Therapeutics, Sidney Kimmel Cancer, Thomas Jefferson University, Woodbury, New Jersey; and.
  • Calais J; Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
  • Tagawa ST; Department of Urology, Weill Cornell Medical College, New York, New York.
  • Gonzalez BD; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida.
J Nucl Med ; 64(6): 869-872, 2023 06.
Article en En | MEDLINE | ID: mdl-36635088
The field of radionuclide therapy (RNT) for prostate cancer (PC) is growing rapidly, with recent Food and Drug Administration approval of the first 177Lu-PSMA ligand. We aimed to develop the first patient-reported outcome (PRO) measure for PC patients receiving RNT. Methods: We identified relevant symptoms and toxicities by reviewing published trials and interviews with PC patients receiving RNT (n = 29), caregivers (n = 14), and clinicians (n = 11). Second, we selected items for measure inclusion. Third, we refined the item list with input from experts in RNTs and PROs. Fourth, we finalized the Functional Assessment of Cancer Therapy-Radionuclide Therapy (FACT-RNT) with patient input. Results: This multistep process yielded a brief 15-item measure deemed by key stakeholders to be relevant and useful in the context of RNT for PC. Conclusion: The FACT-RNT is a new standardized tool to monitor relevant symptoms and toxicities among PC patients in RNT trials and real-world settings.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Próstata Tipo de estudio: Prognostic_studies Límite: Humans / Male Idioma: En Revista: J Nucl Med Año: 2023 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Próstata Tipo de estudio: Prognostic_studies Límite: Humans / Male Idioma: En Revista: J Nucl Med Año: 2023 Tipo del documento: Article